Brain tumors are the leading cause of childhood cancer deaths in developed countries. They also represent the most common solid tumor in this age group, accounting for approximately one-quarter of all pediatric cancers. In collaboration with our clinical partners, our lab is part of an ongoing multi-institutional phase 2 trial of the IDO pathway-inhibitor indoximod utilized in a chemo-immunotherapy regimen on pediatric patients with either recurrent malignant brain cancer or newly diagnosed diffuse intrinsic pontine glioma (DIPG). We deploy analytics based on single-cell RNA sequencing (scRNA-seq) on serial peripheral blood samples in conjunction with T-cell receptor sequencing (scTCR-seq) to understand the effects of therapy on the expression profile and immune landscape of the patients.
Lab Members Involved:
